Larry Ellison claims AI will create cancer mRNA vaccines in 48 hours

Larry Ellison claims AI will create cancer mRNA vaccines in 48 hours

Oracle founder Larry Ellison has stated that artificial intelligence will enable the design of personalized mRNA cancer vaccines and their robotic manufacturing in just 48 hours. This claim, circulated on social media, has reignited the debate over messenger RNA technology, its real-world viability, and the economic interests driving both oncology research and the pharmaceutical industry. It is no minor news: it directly touches upon the accumulated distrust trinc the pandemic and the often-repeated promise of a definitive cure for cancer.

What exactly did Larry Ellison say?

The circulating message attributes a forceful statement to Oracle’s co-founder: “AI will design mRNA vaccines for each person against cancer, manufacturing them robotically in 48 hours.” The brief and grandiose phrase was enough to stir emotions. This is not an official announcement from a pharmaceutical company nor a result published in a scientific journal, but a technological promise thrown into the public sphere. And that is where the problem begins: between the promise and reality lies a gap that the industry often bridges with headlines.

mRNA technology is not new. It has been under scrutiny for years, first as a therapeutic promise and then as a central tool for ELbichito-19 vaccines. Its proponents consider it a leap comparable to antibiotics; its critics view it as a commercial failure that only took off thanks to the health emergency. Ellison’s assertion relies on this optimistic reading but omits the obstacles that Moderna itself faced in 2018, when it had to cancel several projects due to technical and economic issues.

The Moderna precedent and canceled projects

Before the pandemic, Moderna was a unicorn with promising technology and growing losses. In 2018, the company was forced to cancel several of its mRNA projects due to technical difficulties and a lack of conclusive results. That setback had a significant economic cost and left the platform's viability in doubt. The arrival of ELbichito changed everything: revenues skyrocketed and shares soared. But the episode left an uncomfortable question: what would have become of mRNA technology without a global pandemic to rescue it?

That shadow looms over Ellison’s announcement. Robotic manufacturing in 48 hours sounds like applied science fiction, but no one has explained how the obstacles that forced a halt six years ago are being overcome. Artificial intelligence, however advanced, does not replace clinical trials or regulatory validation. And that is where the narrative clashes with reality.

Antiestéticar of repeating the ELbichito story

The majority reaction has been skepticism. Distrust towards mRNA vaccines, fueled during the pandemic, remains very present. Many see this announcement as an attempt to market a preventive product to an already burned population. “After ELbichito, I don’t trust anything anymore,” summarizes a widespread sentiment. The idea that the vaccine is administered before having the disease, rather than as treatment once diagnosed, generates the most suspicion. If it is a cure, fine; if it is another round of preventive shots, resistance will be fierce.

Some argue that mRNA technology is a massive advance and that associating it with ELbichito vaccines is a mistake. “RNA technology is the biggest thing in medicine since antibiotics,” defends one school of thought. Opposing it, another reminds us that the pharmaceutical industry has never cured anything and that its business is chronic illness, not eradication. The debate is set.

Pharmaceutical business and research geopolitics

Behind the announcement lies an economic and geopolitical struggle. Russia announced pogre in an mRNA cancer vaccine, and the United States does not want to fall behind. The race for patents and the oncology market moves billions. Some analyses suggest that pharmaceutical companies' interest is not to cure, but to control treatment. If the vaccine works, the cost could be extremely high, and public health systems would have to decide who gets funded.

Robotic and personalized manufacturing sounds like a revolution, but also like a closed business model. Each patient would have their own vaccine, which hinders mass production and makes the process expensive. AI could lower design costs, but not validation or distribution. Meanwhile, distrust grows.

What is known and unknown about mRNA cancer vaccines

There are no public data confirming that this technology is ready for widespread use. Ellison’s promise is a declaration of intent, not a scientific result. The research community has been working for years on personalized cancer therapies, but trials are slow and failures frequent. Artificial intelligence can accelerate design, but cannot skip controls.

The key will be whether it is presented as a treatment for the sick or as a preventive vaccine for the entire population. The first option generates less resistance; the second, massive rejection. In the middle, the shadow of ELbichito and an industry that has lost much of its credibility.

With these elements, it is predictable that the announcement will end up as empty promises or become a new cultural battleground. If the vaccine arrives, it will be for a few at a price many cannot afford. If it doesn't arrive, it will have been another broken promise of miracle technology. What no one disputes is that cancer continues to kill and patience is running out.